-
Sanofi's 2022Q1 performance: China increased by 13.4%!
Time of Update: 2022-05-30
Although Sanofi announced on February 19 this year that the Phase III study of Dupixent in the treatment of chronic spontaneous urticaria had failed, this quarter, the product still made a number of important progress, including: 1) It was submitted in the United States and Europe for the treatment of nodular urticaria.
-
GSK 2022Q1 results: revenue increased by 32%!
Time of Update: 2022-05-30
307 billion pounds in the first quarter, but due to the supply agreement signed with the government, GSK expects Xevudy's full-year revenue to be close to 2021, about 1.
-
6 days 4 daily limit, 14 days 11 daily limit!
Time of Update: 2022-05-29
This is a "true" story . An unIPO company, by itself, led an established listed pharmaceutical company to gain 4 daily limit within 6 days . Perhaps only the new crown concept stocks can inspire
-
Pfizer's third-generation ALK inhibitor lorlatinib approved in China for the treatment of non-small cell lung cancer
Time of Update: 2022-05-29
In October 2017, Pfizer announced the complete data of the phase II clinical trial of Lorlatinib, which showed that the drug showed clinically meaningful activity in the treatment of lung tumors and brain metastases in patients with ALK-positive and ROS1-positive advanced NSCLC .
-
The most expensive drug in the world!
Time of Update: 2022-05-29
*cc: Calculated at constant exchange rate Among them, Novartis' Spinal Muscular Atrophy (SMA) gene therapy Zolgensma, which has attracted much attention, achieved revenue of US$363 million, an increase of 18% year-on-year, mainly due to the expansion of access to Europe and emerging growth markets .
-
Novartis drastic change: Establishing a chief strategy and growth officer, restructuring will affect thousands of employees?
Time of Update: 2022-05-29
Novartis' global chief executive Vas Narasimhan expects to cut sales and administrative expenses by at least $1 billion a year through 2024 .
5 billion, an increase of 5% year-on-year, of which the sales of the innovative medicine business unit (IM) were approximately US$10.
-
[Heavyweight] In 2021, the sales of drugs in my country's three major terminals and six major markets will reach 1,774.7 billion, a year-on-year increase of 8.0%
Time of Update: 2022-05-29
Judging from the sales distribution of the three major terminals that realize drug sales, public hospitals have the largest terminal market share, accounting for 63.
9% in 2021; public primary medical terminals have a market share of 2021.
-
Over 90% of deaths in Shanghai are over 60 years old. Why is it difficult for the elderly to get vaccinated?
Time of Update: 2022-05-29
Source: Visual China Zhou Chen often encounters situations: elderly people or their families who cannot fully understand them prevaricate or even scold them when they mobilize , "An elderly person may be scared when he sees an injection scene after he arrives, his blood pressure soars to 140, and his daughter thinks we are The work is too simple and rude, and we forcibly tricked him into the vaccination site .
-
Following the "Y Drug", the second CTLA-4 inhibitor will be approved soon, and the race to upgrade the track begins
Time of Update: 2022-05-29
Today, let's sort out the mechanism of action and research and development direction of CTLA-4 inhibitor, the world's first approved immune checkpoint inhibitor.
It is the world's first immune checkpoint inhibitor and the only anti-CTLA-4 monoclonal antibody currently on the market .
-
Pharmaceutical companies say so, but doctors listen like that?
Time of Update: 2022-05-29
After reviewing the conclusions of these studies, the FDA asked a more specific question that became the subject of this study: If the limitations of clinical data (including methodological limitations and practical limitations) are disclosed in drug promotion materials, and the drug has "uncertain clinical value", will it help doctors to interpret clinical data more accurately and effectively?
-
What are the working procedures of the filling machine
Time of Update: 2022-05-27
It is strictly forbidden to have oil stains, liquid medicine or glass debris on the machine, so as to avoid damage to the machine.
Therefore, it is necessary to: (1) During the production process of the machine, remove the liquid medicine or glass debris in time .
-
Fosun Pharma, whose R&D investment ranks among the top 3 in China, is attacking everywhere
Time of Update: 2022-05-26
So far, Fosun Pharma has completed the final piece of the jigsaw puzzle in the prevention and treatment of the new crown, becoming the first and only domestic pharmaceutical company with vaccines, oral drugs and antigen detection products .
-
What should I do if the mold incubator is contaminated?
Time of Update: 2022-05-26
The mold incubator is composed of a box, a disinfection ultraviolet lamp, a heater, a circulating fan, a temperature sensor, an intelligent thermostat, a humidity sensor, a humidifier, a refrigerator, and an over-temperature protector .
Treatment method for mold incubator pollution: 1.
-
China's over 100 billion pharmaceutical companies
Time of Update: 2022-05-26
Industrial chain extension: integration and sharing platform Sinopharm Holding, Shanghai Pharmaceuticals and China Resources Pharma, represented by state-owned holdings, have adopted a strategic layout of upstream and downstream integration, but the focus of the companies is different .
-
Countdown!
Time of Update: 2022-05-26
In addition, the 89 drugs included in Chongqing’s third year of digestion will stop being reimbursed by medical insurance from July 1, 2022; the Qinghai Provincial Medical Insurance Bureau stipulates that the remaining 98 varieties will be transferred in 2022, from January 2023.
-
Impairing $6.6 Billion in Goodwill Sees the Ceiling of Digital Therapeutics from Teladoc
Time of Update: 2022-05-09
The reason for Teladoc's failure in the field of chronic diseases is that it greatly overestimates the scale of convertible users, which in turn depends on two points: the need for users to be managed is not high and the selectivity of the B-end customer base is strong .
-
The world's first panoramic time-space map of life announced!
Time of Update: 2022-05-08
▲Stereo-seq allows scientists to obtain high-resolution transcriptomic information (Image source: Reference [1]) In one of the Cell papers, the team used Stereo-seq to examine early embryonic development in mice between days 9.
-
Serious involution of PD-1?
Time of Update: 2022-05-08
Activity data for the small molecule PD-L1 inhibitor INCB086550 Next, the researchers used a variety of antibodies to characterize the effect of INCB086550 on the formation and internalization of PD-L1 dimers .
-
40th Anniversary of KRAS Discovery What are the strategies for targeting all KRAS mutations?
Time of Update: 2022-05-08
Pan-KRAS-targeted therapy has the potential to treat a broad patient population, including cancers harboring KRAS G12D, G12V, G13D, G12R, G12A mutations, and KRAS wild-type amplification, as well as cancers that are resistant to KRAS G12C inhibitors .
-
Three inspirations from the CDE double antibody R&D guidelines for the industry
Time of Update: 2022-05-08
The document proposes to determine a reasonable R&D project, emphasizes the need to consider the efficacy and safety of double-antibody drugs as a whole new whole, and clearly proposes to "guide antibody design with clinical needs", focusing on target selection, structure Design and optimization provides guidelines for requirements .
